Recently, the Central South University Greater Bay Area Biomedical Achievement Matchmaking Conference & the 5th Health Innovation and Translation Forum was grandly held at the Pingshan District Central Hospital in Shenzhen. Professor Shi Yuan Yuan, founder of Shenzhen Cell Valley, was invited to attend and signed an industry-university-research cooperation agreement on behalf of the company with the Shenzhen Research Institute of Central South University. Centered on the theme "Converging Government, Industry, Academia, and Research; Showcasing New Quality Productivity in Bay Area Medicine and Research," the conference was jointly hosted by the Xiangya School of Medicine of Central South University and its Shenzhen Research Institute. Attendees included senior leaders such as Chen Xiang, Standing Committee Member of the CPC Central South University Committee, Executive Vice President of the university, and Dean of Xiangya School of Medicine; Yang Tao, Standing Committee Member of the CPC Pingshan District Committee and Executive Deputy District Head; and Yang Yifeng, President of Pingshan District Central Hospital. The event brought together representatives from universities, enterprises, medical institutions, and government departments to explore pathways for collaborative innovation in the biomedical field. This significant collaboration between Shenzhen Cell Valley and the Shenzhen Research Institute will focus on core areas including joint R&D, clinical translation, and talent cultivation. It aims to inject new momentum into the high-quality development of the biomedical industry in the Greater Bay Area by integrating the respective strengths and resources of both parties to establish a comprehensive collaborative innovation model encompassing "basic research + clinical translation + industrial application." The two sides will engage in in-depth cooperation centered on joint development of innovative pipelines, targeting major disease areas such as cancer and autoimmune diseases. A key objective is the co-development of cutting-edge cell therapy products like CAR-T and CAR-NK based on retroviral vector technology, thereby accelerating the translation of scientific research achievements from the laboratory to the clinic. Furthermore, leveraging the Precision Medicine Translation Platform of the Shenzhen Research Institute, the partnership will facilitate efficient alignment between clinical needs and technological R&D. Moving forward, both parties will use this agreement as a starting point to continuously explore new models for deep integration between government, industry, academia, and research, contributing to the high-quality development of the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area.